Transforming growth factor β1 (TGF-β1) is a multifunctional cytokine. There is growing evidence that TGF-β1 is involved in the pathogenesis of hypertension and the development of target organ damage in hypertensives. Although several studies have shown that TGF-β1 induced vascular hypertrophy and remodelling in various vascular diseases, there are no longitudinal data on hypertension in the epidemiological studies. The present study tested the hypothesis whether elevated TGF-β1 levels can predict the development of hypertension. In -2004 , 528 subjects received health examinations in Uku town, southwestern Japan. We examined blood pressure (BP), body mass index, and blood test. Data on fasting plasma TGF-β1 were obtained from 528 individuals. Of these, 149 normotensives (BP <140/90 mm Hg without antihypertensive medications) at baseline were followed-up for 14 years.
Original article
Transforming growth factor β1 (TGF-β1) is a multifunctional cytokine that has been linked to myocardial hypertrophy. 1 It has been recently revealed that plasma levels of TGF-β1 are markedly increased in patients with hypertension. 2 However, it is well known that one of the major complications of TGF-β receptor inhibitors for treatment of cancers is hypertension. [3] [4] [5] Several studies in humans and experimental models have shown that the increased myocardial TGF-β expression were associated with cardiac hypertrophy and fibrosis. [6] [7] [8] It has been also suggested that the levels of TGF-β were significantly associated with other organ damage including kidney. 9, 10 Moreover, some life-style such as smoking habit is thought to increase plasma levels of TGF-β1. 11, 12 However, no epidemiological prospective study has investigated the relationship between TGF-β1 and the development of hypertension in normotensives.
Therefore, we conducted a health examination of subjects (n = 528) in a fishing community (Uku town, Nagasaki, Japan) [13] [14] [15] and performed an epidemiological study to examine the relationship between plasma TGF-β1 and hypertension.
METHODS

Study population
In 2002-2004, in a fishing community in southwestern Japan (Uku town), a total of 528 people received health examinations. This town is an isolated island near Fukue city, located in Nagasaki prefecture, and the total population is about 3,700. We have been performing an epidemiological study every year for recent 15 years. All participants approved the blood test. Eventually, complete data set for 528 subjects (190 males and 338 females) was available in this study.
Of 528 participants, 379 subjects were excluded due to no blood tests in 91, hypertensive medication in 201, and hypertensives in 87. Of 149 normotensives (blood pressure [BP] <140/90 mm Hg without antihypertensive medications) at baseline, 9 subjects were unknown and moved, and 7 subjects were dead. Finally, we included 133 subjects in the present study, who were followed-up for 14 years. Of these, 59 subjects developed hypertension. Sample size flow chart was shown in Figure 1 .
Data collection
The medical history, smoking, and alcohol statuses were ascertained by a questionnaire, which we carefully interviewed. Smoking and alcohol were classified as current habitual use or not. Height and weight were measured, and body mass index (BMI: kilograms per meter squared) was calculated as an index of obesity. BP was measured twice with the subjects in the sitting and supine positions. Vigorous physical activity and smoking were avoided for at least 30 minutes before BP measurement. The supine BP with the fifth phase diastolic pressure was used for analysis.
Blood was drawn from the antecubital vein in the morning after 12-hour fast for determinations of lipids (total cholesterol, high-density lipoprotein-cholesterol, and triglycerides), fasting plasma glucose, insulin, blood urea nitrogen, creatinine, uric acid, and TGF-β1. TGF-β1 was measured by Enzyme immune-assay (EIA method). 16 Intra-assay and interassay coefficients of variation of TGF-β1 in a commercially available laboratory (SRL, Fukuoka, Japan) were 1.5% and 3.5%, respectively. All chemistries were measured at a commercially available laboratory (The Kyodo Igaku Laboratory, Fukuoka, Japan).
A 12-lead electrocardiogram allowed estimation of left ventricular (LV) hypertrophy (high-voltage criteria in the Minnesota code: SV 1 + RV 5 ≥ 3.5 mV; where SV 1 is the S-wave voltage in lead V 1 and RV 5 is the R-wave voltage in lead V 5 ). Two-dimensional directed and guided M-mode echocardiographic studies were performed in all subjects by experienced investigators. The LV mass was measured on the M-mode guided echocardiogram, 17 which was derived from the formula described by American Society of Echocardiography (ASE) 18 The mayor and the welfare section of Uku town and the Ethical Committee of Kurume University approved this study. All participants gave informed consent.
Statistical analysis
Because of skewed distributions, the natural logarithmic (ln) transformations were performed for triglycerides, fasting plasma glucose, and insulin. Mean values with upper and lower 95% confidence intervals were exponentiated and presented as geometric mean ± SD, where the SD was approximated as the difference of the exponentiated confidence interval divided by 3.92, which is the number of SD in a 95% confidence interval where data are normally distributed. Results are presented as mean ± SD. The medication for hypertension was coded as dummy variables. Univariate analysis was performed for determinants of plasma TGF-β1 levels in total subjects. To investigate independent determinants of TGF-β1 levels, multiple linear regression analysis adjusted for age and sex was performed in hypertensive subjects. Statistical significance was defined as P < 0.05. All statistical analyses were performed with the use of the SAS system (release 9.4; SAS Institute, Cary, NC).
RESULTS
Cross-sectional study
Characteristics of 528 subjects are presented Table 1 . Mean age was 64.1 years old. Almost half of them have taken antihypertensive treatment and smoking rates were relatively low (23.2% in males and 1.2% in females). The mean values of TGF-β1 were 5.7 ng/ml for males and 5.4 ng/ml for females. In the 528 subjects, systolic BP level (P = 0.002) and smoking habit (P = 0.026) was significantly associated with TGF-β1. No significant association was observed between TGF-β1 and other parameters including hypertensives (data not shown).
Prospective study
Characteristics of 133 normotensives subjects are presented in Table 2 . The mean values of TGF-β1 were 5.9 ng/ ml for males and 4.7 ng/ml for females. To examine the association between TGF-β1 levels and the development of hypertension, we performed logistic regression analysis. Of 133 normotensives at baseline, 59 subjects developed hypertension during the 14-year follow-up. Table 3 shows the results of univariate logistic regression analysis to predict the development of hypertension. Age (P = 0.002), body mass index (P = 0.003), systolic BP (P = 0.008), glucose (P = 0.039), TGF-β1 (P = 0.045), and LV mass index (P = 0.035) were significantly associated with the development of hypertension.
As shown in box plots of plasma TGF-β1 levels stratified by with and without hypertension progression (Figure 2) , mean TGF-β1 levels in subjects with hypertension were significantly higher than those without hypertension (P = 0.030). Optimal plasma TGF-β1 cutoff value for the development of hypertension was examined using receiver-operating characteristic analysis. The calculated cutoff value of TGF-β1 was 8.9 ng/ml with the C-statistics of 0.580. We divided the baseline plasma TGF-β1 levels into 2 groups using the cutoff value. The significant high odds ratio [3.582 (95% confidence interval, 1.025-12.525)] for the development of hypertension was observed in the high group of plasma TGF-β1 level after adjustment for age, sex, systolic BP, body mass index, glucose, and LV mass index, as shown in Table 4 .
DISCUSSION
This is the first prospective study demonstrating the causal relationship between the elevated TGF-β1 and the Data are expressed as mean ± SD, unless otherwise indicated. Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LV, left ventricular; TGF-β1; transforming growth factor β1.
a Log-transformed values were used in analyses. Hypertensives were defines as systolic BP ≥140 and/or diastolic BP ≥90 mm Hg and/or treatment.
development of hypertension. Elevated plasma TGF-β1 levels could predict the development of hypertension in normotensives in a population of community-dwelling Japanese.
Cross-sectional study
Although the number of enrolled subjects in the previous studies was small, less than about 100, 2, 9, 11, 17, 19, 20 the present study examined more than 500, which enables us to examine the distribution of plasma TGF-β1 levels in a general population. The mean levels of TGF-β1 were 5.7 ng/ml for males and 5.4 ng/ml for females (Table 1) .
TGF-β1 is involved in the pathogenesis of hypertension through several mechanisms, 2 including stimulation of endothelin mRNA expression in the vascular endothelium, 21 the increase of renin release from juxtaglomerular cells in the kidney, and the regulation of angiotensin II expression. 22 In univariate analysis in the present study, systolic BP was a significant parameter with TGF-β1 levels and the prevalence of hypertension was not related to TGF-β1 levels (P = 0.137) at baseline (data not shown), which were consistent with the previous study. 2 Although some antihypertensive drugs may affect TGF-β1 levels, we have no data regarding the issue. Further, because TGF-β receptor inhibitors can cause hypertension in the cancer fields, 3 -5 the precise mechanisms should be clarified in future.
TGF-β plays a causal role in myocardial fibrosis and diastolic through fibroblast activation in pressure-overloaded Data are expressed as mean ± SD, unless otherwise indicated. Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; eGFR; estimated glomerular filtration rate; HDL, high-density lipoprotein; LV, left ventricular; TGF-β1, transforming growth factor β1.
a Log-transformed values were used in analyses.
hearts. 8, 23, 24 Schultz et al. 25 demonstrated that TGF-β1 is an important mediator of the hypertrophic growth response of the heart to angiotensin II. In the linear regression analysis in the present study, there was a marginal (P = 0.053) positive correlation between TGF-β1 and LV mass index (data not shown in Table) . The elevated TGF-β1 is related to cardiac hypertrophy in hypertensive subjects. 26 Although the cross-sectional analyses were not able to indicate whether the elevated TGF-β1 levels were the causes or the results of cardiac hypertrophy, the elevated TGF-β1 may be a useful biomarker for LV hypertrophy in hypertensive subjects. Current smoking is significantly associated (P = 0.026) with TGF-β1 in univariate linear regression analysis. In the same districts, we also have demonstrated that current smoking is significantly associated with plasma heat shock protein 27 levels. 27 Nicotine has been reported to promote TGF-β1 and basic fibroblastic growth factor release in bovine aortic endothelial cells. 28 Also, it has been reported that cigarette smoking condensate induced cell adhesion molecules in human endothelial cells through protein kinase C activation, 29 which is a common pathway for TGF-β1 synthesis. Ematjes et al. 11 showed that smoking may be associated with higher production of TGF-β1.
Prospective study
This is the first longitudinal study to demonstrate the hypothesis that high levels of plasma TGF-β1 levels could predict the development hypertension, in subjects without hypertension at baseline. Although a prospective study from Italy has demonstrated that higher TGF-β1 levels are associated with the development of hypertensive renal disease, they did not demonstrate the association of TGF-β1 with the development of hypertension. 30 Rather than the development of hypertension, there are some manuscripts regarding the excess risk of renal diseases. 31, 32 The mechanisms are not still clear; however, TGF-β1 is a fibrogenic cytokine that plays a key role in the pathogenesis of renal diseases, and TGF-β1 blockade may prevent renal disease progression. 1, 33 Otherwise, it may be caused by the racial difference, both of which 1, 33 were analyzed in African Americans. In the present study, we demonstrated not only our hypothesis but also the extent and the magnitude of the association; that is, subjects with plasma TGF-β1 levels ≥9.0 ng/ml were shown to have a 3.58-fold higher risk of developing hypertension in 14 years than those with TGF-β1 levels ≤8.9 ng/ml.
It is interesting to note that LV mass index is marginally (P = 0.053) and significantly (P = 0.035) associated with TGF-β1 levels in our cross-sectional and longitudinal studies, which are consistent with the previous studies. 19, 34, 35 In the present study, multiple linear regression analysis showed that LV hypertrophy in electrocardiogram and LV mass index in echocardiogram were significantly associated with TGF-β1 levels in hypertensive subjects adjusted by confounding factors (data not shown). 26 Almendral et al. 16 reported the significant association (P < 0.01) between TGF-β1 and LV mass in hypertensive patients.
We did not show the dose-dependency of TGF-β1 levels to predict the development of hypertension, which suggests that a cutoff value may exist. Accordingly, we calculated cutoff values by receiver-operating characteristic curves, which was 8.9 ng/ml. Taken together, these findings indicate that this cutoff value may be relevant when considering the association of TGF-β1 levels with the development of hypertension. Subjects with baseline TGF-β1 levels ≥9.0 ng/dl were 3.58 times more likely to develop hypertension after 14 years compared with subjects with TGF-β1 levels ≤8.9 ng/dl. Our findings may be pertinent in the context of a pathophysiological role of TGF-β1 in the general population.
Study limitations and perspective
There were several limitations in this study. First, this study was conducted in Japan, where the incidence of hypertension is relatively high compared with Caucasians. Second, 16 subjects (10.7%) were lost to follow-up, because of death, moved or unknown to participate in re-examination. Therefore, we limited our analyses to subjects who completed baseline and follow-up examinations. Third, the sample size was relatively small, although it was larger than those in the previous studies. 2, 9, 11, 17, 19, 20 A final limitation is that we could not clarify the types of antihypertensive drugs used during the 14-year period, because antihypertensive drugs were changed frequently by primary physicians to control BP or for adverse effects.
Cross-sectional study showed that LV mass index and LV hypertrophy in electrocardiogram were significantly associated with TGF-β1 levels in hypertensive subjects. Prospective study showed that the elevated TGF-β1 predicted the development of hypertension in normotensives at baseline. Thus, it would be useful to examine whether TGF-β1 blockers could be effective for hypertensives to decrease LV hypertrophy and hopefully further to improve LV diastolic dysfunction, and even for normotensives to prevent the development of hypertension in subjects with high plasma TGF-β1 levels.
In conclusion, the present study demonstrated that elevated TGF-β1 levels predicted the development of hypertension after 14 years in subjects without hypertension at baseline in a general population.
